Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · February 09, 2023

Effect of Elexacaftor/Tezacaftor/Ivacaftor on Annual Rate of Lung Function Decline in Patients With Cystic Fibrosis

Journal of Cystic Fibrosis

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Cystic Fibrosis
EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS
J Cyst Fibros 2022 Dec 27;[EPub Ahead of Print], T Lee, GS Sawicki, J Altenburg, SJ Millar, JM Geiger, MT Jennings, Y Lou, LJ McGarry, K Van Brunt, RW Linnemann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading